Appropriate clinical use of statins: A discussion of the evidence, scope, benefits, and risk

Alternative Therapies in Health and Medicine

Volumn 19, Issue SUPPL.1, 2013, Pages 14-25

  Perlmutter, David ^a,b   Golomb, Beatrice ^c   Sinatra, Stephen ^d   Campbell, Andrew W ^e  

^a UNIVERSITY OF MIAMI   (United States)

^b Institute for Functional Medicine in Gig Harbor   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL MEDICINE; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; METHODOLOGY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL MEDICINE; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884249710     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35(11):2390-2392.
2. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76(9):113C-117C.
3. Ridker PM, Danielson E, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
4. Nakazato R, Gransar H, et al. Strains use coronary artery plaque composition: results from the International Multicenter CONFIRM Registry. Atherosclerosis. 2012;225(1):148-153.
5. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012;89(8):1165-1171.
6. No authors listed. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
7. Culver, AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med. 2012;172(2):144-152.
8. Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology. 2012;79(10):1019-1026.
9. Bruehl H, Sweat V, Tirsi A, et al. Obese adolescents with type 2 diabetes mellitus have hippocampal and frontal lobe volume reduction. Neurosci Med. 2011;2(1):34-42.
10. Reitz C, Luchsinger J, Tang MX, et al. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology. 2005;64(8):1378-1383.
11. Elias PK, Elias MF, D'Agostino RB, et al. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med. 2005;67(1):24-30.
12. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350(9085):1119-1123.
13. Jonsson A, Sigvaldason H, Sigfusson N. Total cholesterol and mortality after age 80 years. Lancet. 1997;350(9093):1778-1779.
14. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation. 1999;99(6):779-785.
15. de Lorgeril M, Salen P. Recent cholesterol-lowering drug trials: new data, new questions. J Lipid Nutr. 2010;19(1):65-92.
16. Bradford RH, Shear CL, Chremos AN. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667-73.
17. Bowden J, Sinatra S. The Great Cholesterol Myth: Why Lowering Your Cholesterol Won't Prevent Heart Disease-and the Statin-Free Plan That Will. Beverly, MA: Fair Winds Press; 2012.
18. Gaist D, Jeppesen M, Andersen LA, Garcia Rodriguez J, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58(9):1333-1337.
19. No authors listed. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA. 1976;235(8):825-827.
20. Davey Smith G, Song F, Sheldon T. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306(6889):1367-1373.
21. Silberberg JS, Henry DA. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 2. Implications for heart disease prevention in Australia. Med J Aust. 1991;155(10):670-674.
22. Tonkin AM, Eckermann S, White H, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 75 years compared with younger patients: results from the LIPID Study. Am Heart J. 2006;151(6):1305-1312.
23. Ford I, Blauw GJ, Murphy MB. A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med. 2002;3(1):8.
24. Ginsberg HN, Bonds DE, Lovato LC. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):56i-67i.